Age-Related Macular Degeneration (AMD) Market Forecast Report and Company Analysis 2025-2033 Featuring Hoffmann - La Roche, Bayer, Abbvie, GSK, Novartis, Regeneron Pharma, Bausch, Alimera Science
The aging population, rising rates of lifestyle-related risk factors, improved diagnostic tools, more awareness, and the creation of novel AMD treatments and therapies are the main factors propelling the Age-Related Macular Degeneration (AMD) market.
Age-Related Macular Degeneration (AMD) Market
Dublin, May 15, 2025 (GLOBE NEWSWIRE) -- The "Age-Related Macular Degeneration (AMD) Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" report has been added to ResearchAndMarkets.com's offering.Age-Related Macular Degeneration (AMD) Market is expected to reach US$ 20.88 billion by 2033 from US$ 11.42 billion in 2024, with a CAGR of 6.94% from 2025 to 2033
In affluent societies, age-related macular degeneration (AMD) is the primary cause of blindness in older adults. It is an age-related eye condition that gradually impairs the central vision required for reading, driving, facial recognition, and color vision. As AMD worsens, central vision is lost, impairing quality of life by preventing many patients from reading, writing, or recognizing color and detail. Recent advancements in genetic technologies have led to the discovery of several variants that have been demonstrated to have distinct relationships with AMD, despite the fact that the precise functional pathophysiology of AMD is still unclear.The macula, the core portion of the retina, gradually degenerates in age-related macular degeneration, resulting in central vision loss. Based on its clinical characteristics, such as drusen, aberrant pigmentation, atrophy of the retinal pigment epithelium (RPE), and exudative choroidal neovascularization (CNV), age-related macular degeneration can be categorized as early, intermediate, or late. Another way to describe age-related macular degeneration is as wet (exudative or neovascular) or dry (atrophic or non-neovascular).The market is expected to be primarily driven by the introduction of new products, a robust product pipeline, and an increase in the prevalence of AMD. According to the Population Reference Bureau, the number of Americans 65 and older is expected to increase by 47%, from 58 million in 2022 to 82 million in 2050. Today, the U.S. population is older than it has ever been.One of the main elements driving category expansion is the aging population. About 200,000 new cases of wet AMD are discovered in North America each year, according to Genentech. Wet AMD causes 90 percent of legal blindness but only accounts for about 10 percent of events. Because of the unchecked proliferation of new blood vessels in the eye, which results in fluid leaking into the macula, this advanced variety can cause rapid and severe vision loss.Growth Drivers for the Age-Related Macular Degeneration (AMD) Market
Innovative Treatment OptionsThe management of age-related macular degeneration (AMD) has changed dramatically as a result of the introduction of novel medications, including as anti-VEGF (vascular endothelial growth factor) therapy. These therapies have been shown to stabilize or enhance vision in a large number of patients by preventing aberrant blood vessel formation in the retina, which is a defining feature of wet AMD.
Furthermore, by focusing on the genetic defects that cause AMD, advances in gene therapy hold the promise of treating the disease's underlying causes. The market is expanding as a result of these new treatment options, which can delay the course of AMD and enhance patients' quality of life. It is anticipated that more ground-breaking treatments will surface as research progresses, increasing the range of available treatments and improving patient outcomes.Increasing AwarenessGrowing public knowledge of age-related macular degeneration (AMD) is a major factor in the market's growth. The public is being educated about the symptoms, risk factors, and significance of early diagnosis through awareness programs run by patient advocacy organizations, healthcare organizations, and ophthalmology experts.
People are more inclined to seek early screening as they become more knowledgeable about the illness, which can result in earlier therapies that can improve outcomes. More people are identifying AMD in its early stages thanks to better access to healthcare, especially in poorer nations. The market for AMD is developing as a result of increased awareness and proactive healthcare strategies, which are driving up demand for diagnostic and treatment solutions.Rising Healthcare InvestmentsNew and better treatments for Age-Related Macular Degeneration (AMD) are being developed more quickly thanks to increased funding for ophthalmology and retinal research. More research into improved diagnostic methods, cutting-edge treatments, and even cures for AMD is being made possible by increased funding from the public and commercial sectors.
Additionally, this investment is supporting clinical trials for potential medications and therapies that could provide better treatments for both wet and dry forms of AMD. The market for AMD is seeing the introduction of innovative treatments and diagnostic tools due to technological breakthroughs and an increasing emphasis on retinal health. These developments will ultimately improve patient care and propel market expansion.Challenges in the Age-Related Macular Degeneration (AMD) Market
High Treatment CostsPatients may need repeated injections over long periods of time, and treatments for Age-Related Macular Degeneration (AMD), particularly anti-VEGF medications, can be costly. Both patients and healthcare systems may experience severe financial hardship as a result of these exorbitant expenses, especially in areas with low and moderate incomes where access to cutting-edge treatments may be restricted.Lack of Early DiagnosisIn its early stages, patients may not detect any signs of age-related macular degeneration (AMD), which frequently develops slowly. Because of this, many people wait until they have experienced severe vision loss before seeking medical help. Early detection can be difficult due to the disease's sluggish progression, and by the time patients receive a diagnosis, the illness is frequently well advanced.
Company Analysis: Overview, Key Persons, Recent Development & Strategies, Financial Insights
Hoffmann - La Roche Ltd.
Bayer AG
Abbvie
GSK Plc
Novartis AG
Regeneron Pharmaceuticals
Bausch Health Companies Inc.
Alimera Sciences Inc.
Key Attributes:
Report Attribute
Details
No. of Pages
200
Forecast Period
2024 - 2033
Estimated Market Value (USD) in 2024
$11.42 Billion
Forecasted Market Value (USD) by 2033
$20.88 Billion
Compound Annual Growth Rate
6.9%
Regions Covered
Global
Key Topics Covered: 1. Introduction2. Research Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Global Age-Related Macular Degeneration Market6. Market Share6.1 Disease Type6.2 Product6.3 Distribution Channel6.4 Country7. Disease Type7.1 Dry Age-Related Macular Degeneration Market7.2 Wet Age-Related Macular Degeneration Market8. Product8.1 Eylea8.2 Lucentis8.3 Beovu8.4 Others9. Distribution Channel9.1 Hospital Pharmacy9.2 Specialty Pharma9.3 Online Pharmacy10. Country10.1 North America10.1.1 United States10.1.2 Canada10.2 Europe10.2.1 France10.2.2 Germany10.2.3 Italy10.2.4 Spain10.2.5 United Kingdom10.2.6 Belgium10.2.7 Netherlands10.2.8 Turkey10.3 Asia Pacific10.3.1 China10.3.2 Japan10.3.3 India10.3.4 Australia10.3.5 South Korea10.3.6 Thailand10.3.7 Malaysia10.3.8 Indonesia10.3.9 New Zealand10.4 Latin America10.4.1 Brazil10.4.2 Mexico10.4.3 Argentina10.5 Middle East & Africa10.5.1 South Africa10.5.2 Saudi Arabia10.5.3 UAE11. Porter's Five Analysis11.1 Bargaining Power of Buyers11.2 Bargaining Power of Suppliers11.3 Degree of Rivalry11.4 Threat of New Entrants11.5 Threat of Substitutes12. SWOT Analysis12.1 Strength12.2 Weakness12.3 Opportunity12.4 Threat13. Key Players Analysis
For more information about this report visit https://www.researchandmarkets.com/r/ock5te
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
Age-Related Macular Degeneration (AMD) Market
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
44 minutes ago
- Yahoo
Prince Harry Didn't Mean to ‘Attack' Royal Family With Bombshell BBC Interview, Biographer Says
Prince Harry apparently didn't mean any harm with his bombshell BBC interview — at least, according to a royal expert. 'It wasn't meant to be an attack, but it would be seen as one,' royal biographer Valentine Low told People in an interview published on Tuesday, June 3, regarding last month's interview. Harry, 40, offered a public plea to his father, King Charles III, asking for a reconciliation with his family during the May 2 interview. The Duke of Sussex claimed that his father 'won't speak to me' during the chat. (The interview came after Harry lost the appeal in his battle for government-funded security in the U.K.) 'I would love reconciliation with my family. There's no point in continuing to fight anymore,' Harry also said at the time. 'Life is precious. I don't know how much longer my father has.' Royal Family Reportedly Had 'Brief' Heads-Up About Prince Harry's Bombshell Interview Low told People that Harry's comments weren't a positive step toward the possibility of a future reconciliation with his father or brother, Prince William. 'It makes Charles reaching out even harder,' the Power and the Palace author added, noting that 'there is not a good angel' telling Charles to 'be a good dad and make the first move.' A separate royal expert shared a similar sentiment, telling Us Weekly exclusively last month that Charles, 76, is unlikely to reach out to Harry. 'The King is only hewing to a long-standing royal practice of not dignifying something by commenting on it. The Palace does not want to give oxygen to Harry's remarks,' royal expert Christopher Andersen said. 'King Charles has a lot on his plate as it is — there is no upside to his getting into a public quarrel with his son.' Prince William Is 'Done With Harry,' Will Not Publicly Respond to Brother's Comments, Source Says Fellow royal expert Richard Fitzwilliams also told Us that Harry's comments regarding Charles' health 'are unlikely to have gone down well' within the family. (Charles was diagnosed with an undisclosed form of cancer in February 2024.) 'If Harry really wants to reconcile with his family, he has an odd way of showing it,' Andersen also told Us. 'He slams his father for interfering in the trial, then says the Palace rigged the outcome, then accuses the Royal Family of not caring about the safety of his wife and children, and winds up declaring that for now he can't foresee any scenario in which he would take his family to the U.K.,' Andersen continued. 'Harry delivered the coup de grace when he said he wanted to bury the hatchet with his father because he doesn't know how much time the King has left to live.'
Yahoo
an hour ago
- Yahoo
Cannabis Research Reveals Optimal Water Activity Levels for Enhanced Pre-Roll Quality and Profitability
First-Of-Its-Kind, Peer-Reviewed Study Combines Laboratory Analysis With Consumer Testing To Optimize Cannabis Smoking Experience RENTON, Wash., June 05, 2025 (GLOBE NEWSWIRE) -- Custom Cones USA, in partnership with DaySavers, the Cannabis Research Coalition, and The Network of Applied Pharmacognosy (NAP), shares key findings from Phase I Science of Smokability study, a multi-year research project that is transforming understanding of cannabis cultivation, processing, and consumption. The revolutionary study, led by Dr. Allison Justice, Dr. Miyabe Shields, Dr. Riley Kirk, and Dr. Markus Roggen, represents the first peer-reviewed scientific assessment to examine how various cultivation and production techniques affect cannabis products from the consumer perspective, combining laboratory smoking machine analysis with comprehensive consumer surveys. Key Findings Reveal 0.65 aW as Optimal Water Activity Level Phase I research focused on water activity and moisture content effects on cannabis pre-rolls, with results demonstrating that products maintained at 0.65 aW (water activity) consistently delivered superior performance across multiple metrics: Cannabinoid Delivery: Pre-rolls at 0.65 aW produced the highest cannabinoid concentration in smoke, with 0.85 aW samples delivering only 30% of the cannabinoid content compared to optimal levels Terpene Content: The 0.65 aW samples yielded the highest terpene content, delivering more pronounced flavor profiles Consumer Experience: Survey participants reported that 0.65 aW pre-rolls provided a less irritating smoking experience, while 0.45 aW samples produced harsher, more irritating experiences Significant Financial Implications for Cannabis Producers The study reveals substantial economic benefits for producers maintaining proper water activity levels. The research indicates that the difference between 0.45 aW and 0.65 aW water activity levels corresponds to approximately 18.14 grams per pound of flower—representing potential revenue gains of $27.20 per pound at an assumed market price of $1.50 per gram. "This represents about 4% of revenue per pound of flower," explained Harrison Bard, CEO of Custom Cones USA. "For cannabis producers, optimizing water activity levels can simultaneously improve product quality while enhancing profitability." Innovative Research Methodology Sets New Industry Standard Unlike previous cannabis studies, the Science of Smokability employs a unique dual-methodology approach: Laboratory Analysis: Utilizing sophisticated smoking machines and Combustion Smoke Analyzer SCS technology to measure precise cannabinoid and terpene concentrations in smoke Consumer Testing: Comprehensive surveys from paid participants who received pre-rolls in specialized airtight containers to maintain specific water activity levels The study examined high-quality hemp pre-rolls from The Hemp Mine's "FunDip" strain, stabilized at three different water activity levels using digital hygrometers, 0.45 aW, 0.65 aW, and 0.85 aW. Pre-rolls were manufactured on professional pre-roll machines to ensure consistency. 'The Cambustion machine allowed us to test the composition of the smoke instead of the raw material (flower),' said Dr. Shields. 'Every time we light up, there's a chemical reaction, and the smoking machine allows us to look at what molecules are reaching our lungs after they've been smoked.' When combined with consumer feedback, the results provide a comprehensive view of how different production and cultivation variables impact the final consumer version of products. Industry Impact and Implications The research underscores the critical importance of proper curing and moisture management in cannabis production. As the study authors note: "By optimizing water activity levels, it may be possible to enhance the delivery of desirable compounds, such as cannabinoids and terpenes while minimizing the presence of potentially harmful elements." The findings have immediate practical applications for cannabis producers using automated pre-roll filling machines, which typically benefit from lower moisture content around 9%, corresponding to approximately 0.65 aW. 'Our results emphasize that staying as close as possible to the 0.65 threshold allows a higher quality smoking experience,' said Dr. Kirk. About the Science of Smokability Study The Science of Smokability is a multi-year research initiative spearheaded by Custom Cones USA and DaySavers, in partnership with leading cannabis research organizations, the Cannabis Research Coalition and The Network of Applied Pharmacognosy (NAP). The study aims to provide evidence-based insights into cannabis cultivation, processing, and consumption through rigorous scientific methodology. Phase I of the Science of Smokability focused on the effects of water activity and moisture content on the smoking process. Phase II will look at the impact of nutrients on the smokeability and chemistry of smoking. About Custom Cones USA Founded in 2017 by Harrison Bard and Fredrik Rading, Custom Cones USA is a leading pre-roll resource in the cannabis industry. The team has a wealth of knowledge about all aspects of pre-roll manufacturing and the entire pre-roll sector of the cannabis space. From custom-branded pre-rolled cones and wholesale bulk cones, to completely customized pre-roll packaging projects and pre-roll machines, they offer expertise and solutions to companies big and small in all sectors of the pre-roll space. Custom Cones USA wants to help their customers operate with relative ease and ensure both the companies and their customers to have the highest quality smoking experience. Media Contact: Clarissa Colondo customcones@ Editor's Note: Content, brand logos, and additional data visualizations are available for media or brand use with attribution. Interview opportunities with Custom Cones USA analysts are available upon in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Nanotechnology in Cancer Treatment Market Positioned for Transformational Growth by 2029
'Explore how nanomedicine and targeted therapies are shaping the future of cancer care in BCC Research's global market analysis of nanotechnology in oncology.' Boston, June 05, 2025 (GLOBE NEWSWIRE) -- As cancer prevalence continues to rise globally, nanotechnology in cancer treatment is emerging as a transformative force in oncology. Leveraging nanoscale drug delivery systems and precision-targeting techniques, companies such as AstraZeneca, F. Hoffmann-La Roche Ltd., and Bristol-Myers Squibb are developing next-generation solutions to enhance therapeutic effectiveness while minimizing harm to healthy cells. According to the report, growing cancer prevalence, rising government funding, and increased pharmaceutical R&D spending are reshaping innovation strategies across the oncology landscape. The global market is projected to grow at a CAGR of 17.4% from 2024 to 2029. As North America continues to lead market expansion and new nanomedicine applications evolve globally, stakeholders must navigate regulatory complexity, manufacturing scalability, and long-term safety considerations to harness the full potential of this technology. Market Overview: Key Insights and Forecast BCC Research's latest report, Nanotechnology in Cancer Treatment: Technologies and Global Markets, delivers a detailed evaluation of the evolving oncology landscape through the lens of nanomedicine. It explores how advances in nanostructured materials, targeted delivery systems, and diagnostic innovations are shaping the future of cancer treatment across major regions. The global market was valued at $102.4 billion in 2023 and is projected to reach $265.4 billion by the end of 2029. The report delivers forward-looking insights based on current market trends and expected developments over the forecast period. It provides a strategic analysis of major segments by product type and cancer type, along with comprehensive coverage of revenue trends, regulatory frameworks, ESG priorities, technological advancements, and regional market shifts. Market Leadership in Transition The cancer nanomedicine space is evolving rapidly, with companies investing in product differentiation and late-stage R&D. Liposomes remain the most commercially established carriers, while polymeric nanoparticles and dendrimers are seeing increased use due to their payload capacity and tumor selectivity (Chapter 6: Market Segment Analysis). Leading companies such as Pfizer, Novartis AG, and Jazz Pharmaceuticals are developing tailored nanocarrier systems for specific cancer indications, with a focus on breast and lung cancers. These therapies are being designed for better tumor penetration, reduced off-target toxicity and improved treatment outcomes (Chapter 7: Competitive Intelligence). Emerging Technologies and Investment Trends Innovation in nanomedicine is being fueled by multifunctional systems that integrate diagnosis, therapy, and monitoring. Technologies including quantum dots, cancer stem cell-targeting particles, and nanorobotics are moving closer to clinical translation, offering new capabilities in image-guided therapy and adaptive dosing. Strong capital inflow and increased partnerships between biotech firms and research institutions are accelerating development across early and mid-stage pipelines. These trends are unlocking commercialization potential, especially in minimally invasive therapies and immuno-nanomedicine (Chapter 5: Emerging Technologies and New Developments). Pipeline Assessment and Applications The oncology pipeline is steadily embracing nanotechnology as a cornerstone for targeted treatment development. Companies are advancing nanoparticle-based drug carriers with enhanced tumor penetration, improved bioavailability and reduced toxicity. These innovations are driving late-stage R&D across different types of cancers, such as breast and lung cancers, leukemia and melanoma. In parallel, there is growing interest in integrating diagnostic and therapeutic functions into single nanosystems. Platforms capable of simultaneous drug delivery and real-time tumor tracking are gaining momentum, offering the potential for adaptive dosing and early relapse detection (Chapter 6: Market Segment Analysis). Regulatory and Access Challenges Regulatory agencies, such as the U.S. FDA, European Medicines Agency (EMA), and other international bodies, are actively evolving frameworks to support the safe and effective approval of nanoscale cancer therapies. As manufacturers scale production, they must comply with stringent requirements related to materials handling, product traceability and lifecycle oversight (Chapter 4: Regulatory Landscape). Challenges such as development costs, access limitations in low-income regions, and a shortage of oncology specialists trained in nanomedicine are slowing down broader adoption. Addressing these issues is essential to achieving long-term growth and equitable global impact (Chapter 3: Market Dynamics). Strategic Outlook: The Road Ahead With nanotechnology's role in oncology continuing to expand, companies are aligning R&D with long-term goals around innovation, clinical efficacy, and accessibility. Key companies are developing platforms that support patient-centered care, data-driven treatment personalization, and integration across diagnostic and therapeutic pathways (Chapter 2: Market Overview). As infrastructure improves and global interest in targeted therapies grows, nanomedicine is expected to become a cornerstone of modern cancer care. Firms prioritizing early diagnosis, adaptive delivery and long-term monitoring will be best positioned to lead the market forward (Chapter 7: Competitive Intelligence). Report Synopsis Report Metric Details Base year considered 2023 Forecast period considered 2024-2029 Base year market size $102.4 billion Market size forecast $265.4 billion Growth rate CAGR of 17.4% for the forecast period of 2024-2029 Segments covered Product type and cancer type Regions covered North America, Europe, Asia-Pacific, South America, Rest of the World Countries covered The U.S., Canada, Mexico, Germany, France, Italy, Spain, the U.K., Austria, Sweden, Denmark, Poland, Turkey, Switzerland, the Netherlands, China, Japan, India, South Korea, Australia, Thailand, Singapore, Malaysia, New Zealand, Vietnam, Brazil, Argentina, Colombia, Paraguay, Peru, Middle East and Africa Market drivers Increasing prevalence of cancer cases globally. Rise in government funding and pharmaceutical R&D spending. Nanoparticles in cancer treatment: Advantages. Precision targeting of cancer cells with nanomaterials. Additional Insights: Ultra-small and highly efficient: Nanoparticles are often smaller than a single cell; thus, it is easier for them to penetrate tumors and deliver drugs directly to cancer cells. Stealth functionality: These particles can be engineered to "cloak" themselves from the immune system, allowing them to circulate longer within the bloodstream. Multifunctional carriers: Nanoparticles can transport multiple drugs simultaneously, enabling combination therapies in a single delivery. Energy-interactive: They can absorb energy from external sources, supporting their role in advanced imaging or therapeutic enhancement. Next-level diagnostics: Nanoparticles can serve as highly sensitive imaging agents, enhancing early diagnosis and treatment precision. Leading companies include: AstraZeneca Baxter Boston Scientific Corp. Bristol-Myers Squibb Co. F. Hoffmann-La Roche Ltd. Jazz Pharmaceuticals Inc. Les Laboratoires Servier Novartis AG Pfizer Inc. Teva Pharmaceutical Industries Ltd. Navigate Uncertainty with ConfidenceIn times of rapid change and uncertainty, having the right insights can make all the difference. At BCC Research, we are here to support innovation and help you stay ahead. Our custom research reports provide a comprehensive, 360-degree view of your market landscape, providing you with the clarity you need to make informed decisions. We believe that timely, expert market intelligence should be accessible to all. That is why, for a limited time, we are offering 30% off the price of any BCC Research report to help more organizations gain access to our latest data and insights. Get your copy of the report directly from BCC Research. To request more information or complete your purchase, connect with us at info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. CONTACT: BCC Research Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USA Email: info@ Phone: +1 781-489-7301
